MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research

Highlights • Transgenic models of amyloid and tau pathology have been used as platforms for the development of PET imaging biomarkers. • MicroPET constitutes a powerful strategy for in vivo assessment of pathophysiological processes in transgenic models. • The smaller brain volume of mice, the heter...

Full description

Saved in:
Bibliographic Details
Published inTrends in neurosciences (Regular ed.) Vol. 37; no. 11; pp. 629 - 641
Main Authors Zimmer, Eduardo R, Parent, Maxime J, Cuello, A. Claudio, Gauthier, Serge, Rosa-Neto, Pedro
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.11.2014
Elsevier Sequoia S.A
Subjects
Alzheimer Disease - diagnosis
Alzheimer Disease - pathology
Alzheimer's disease
amyloid
Amyloid beta-Peptides - metabolism
Animals
Brain - diagnostic imaging
Disease Models, Animal
Humans
Medical imaging
microPET
neurodegeneration
Neuroimaging
Neurology
positron emission tomography
Positron-Emission Tomography - methods
Propagation
radiopharmaceuticals
Tomography
Transgenic animals
neurodegeneration
radiopharmaceuticals
amyloid
microPET
positron emission tomography
Alzheimer's disease
Online AccessGet full text

Cover

More Information
Summary:Highlights • Transgenic models of amyloid and tau pathology have been used as platforms for the development of PET imaging biomarkers. • MicroPET constitutes a powerful strategy for in vivo assessment of pathophysiological processes in transgenic models. • The smaller brain volume of mice, the heterogeneity of model phenotypes, and the lack of harmonized acquisition protocols contribute to the variability across studies. • Longitudinal assessment using transgenic rats is a reasonable strategy for increasing reproducibility and maximizing translational value.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0166-2236
1878-108X
DOI:10.1016/j.tins.2014.07.002